Vancouver, British Columbia–(Newsfile Corp. – November 19, 2025) – NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) (“NervGen” or the “Company”), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other traumatic and neurologic disorders, today announced that it has completed its previously announced non-brokered private placement (the “Non-Brokered Unit Offering”) to certain institutional investors and other accredited investors. The financing included participation from new and existing investors, including SCI Ventures and the Paul and Phyllis Fireman Charitable Foundation.

Pursuant to the Non-Brokered Unit Offering, NervGen issued 4,785,674 units of the Company (the “Units”) at a price of US$2.10 per Unit

See Full Page